StreetInsider.com News Articles

Tempus AI launches OneOme pharmacogenomics testing nationally

Wed, 22 Jul 2026 08:31:32 -0400

Tempus AI, Inc. (NASDAQ: TEM) has launched its OneOme pharmacogenomics testing solution nationally, following its acquisition of OneOme in November 2025, according to a company statement.

The launch introduces the RightMed Comprehensive test, a 27-gene germline pharmacogenomics laboratory-developed test designed to analyze a patient's inherited genetic traits. Standalone single-gene DPYD and UGT1A1 tests are also available. The tests evaluate how a patient's genetic profile may influence drug response, toxicity risk, or optimal dosage. Results are delivered in under five days on average from sample receipt.

The FDA updated safety labeling for capecitabine and fluorouracil in February 2026, recommending DPYD testing prior to

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Wed, 22 Jul 2026 08:30:00 -0400

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. Following its acquisition of OneOme in November 2025, Tempus has fully integrated these capabilities to expand its comprehensive precision medicine portfolio, bridging a critical gap between genomic tumor profiling and how a patient's body actually processes treatment.

"Answering the urgent demand for immediate, reliable medication safety insights is a clinical imperative,

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Wed, 22 Jul 2026 08:30:00 -0400

"Answering the urgent demand for immediate, reliable medication safety insights is a clinical imperative,

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Wed, 22 Jul 2026 08:30:00 -0400

"Answering the urgent demand for immediate, reliable medication safety insights is a clinical imperative,

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Wed, 22 Jul 2026 08:30:00 -0400

"Answering the urgent demand for immediate, reliable medication safety insights is a clinical imperative,

Form 8-K Tempus AI, Inc. For: Jul 20

Mon, 20 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260720/26790449.html

Form 8-K Tempus AI, Inc. For: Jul 20

Mon, 20 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260720/26790449.html

Jefferies Reiterates Underperform Rating on Tempus AI Inc (TEM)

Mon, 20 Jul 2026 16:54:24 -0400

Jefferies analyst Tycho Peterson reiterated an Underperform rating and $35.00 price target on Tempus AI Inc (NASDAQ: TEM).

The analyst commented: 'This morning, TEM announced the acquisition of PSNL for a net EV of $1.5B (remaining 81% stake) with the deal financed in stock (cash option). While we are constructive on the science behind PSNL's MRD test, the deal represents a sharp pivot from TEM's recent commentary at the 5/29 analyst day on this specific deal providing no net income benefit, and we question if the rationale is intended to offset a slowing core diagnostics business. Reiterate Underperform."

For an analyst ratings

Canaccord Reiterates Buy Rating on Tempus AI Inc (TEM)

Mon, 20 Jul 2026 13:30:28 -0400

Canaccord analyst Kyle Mikson reiterated a Buy rating and $80.00 price target on Tempus AI Inc (NASDAQ: TEM).

The analyst commented: "We reiterate our BUY rating on Tempus AI (TEM) shares and maintain our price target at $80. Before the market open on Monday, July 20, the company announced it has entered into a definitive agreement to acquire Personalis (PSNL). The acquisition (currently structured as an all-stock transaction for roughly $1.7 billion in total enterprise value) will expand Tempus' capabilities in minimal residual disease (MRD) and further enhance the company's ability to support patients (and biopharma companies). For background, Personalis offers

Needham on Tempus AI Inc (TEM): 'Buyers of any weakness related to the transaction'

Mon, 20 Jul 2026 12:51:26 -0400

Needham analyst Ryan Macdonald reiterated a Buy rating and $75.00 price target on Tempus AI Inc (NASDAQ: TEM).

The analyst comments "We reiterate our Buy rating and $75 price target on Tempus AI (TEM) following company's announcement to acquire Personalis in all stock transaction valued at $1.7B EV ($1.5B net of TEM current ownership), with an option for 50% of the transaction to be funded in cash. While the stock has sold off, we believe the strategic value is misunderstood as Personalis significantly enhances Tempus' offerings in the $20B+ MRD market, which has sub-10% penetration today, while the full force of

Needham on Tempus AI Inc (TEM): 'Buyers of any weakness related to the transaction'

Mon, 20 Jul 2026 12:51:26 -0400

Needham analyst Ryan Macdonald reiterated a Buy rating and $75.00 price target on Tempus AI Inc (NASDAQ: TEM).

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Mon, 20 Jul 2026 11:54:45 -0400

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner.

For a free consultation, please visit https://julieholleman.com/personalis-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com.

Personalis is a precision oncology company that develops advanced genomic tests designed to detect and monitor cancer. The company has established itself as a leader in molecular residual disease ("MRD")

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Mon, 20 Jul 2026 11:54:45 -0400

For a free consultation, please visit https://julieholleman.com/personalis-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com.

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Mon, 20 Jul 2026 11:54:45 -0400

For a free consultation, please visit https://julieholleman.com/personalis-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com.

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Mon, 20 Jul 2026 11:54:45 -0400

For a free consultation, please visit https://julieholleman.com/personalis-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com.

Needham Downgrades Personalis (PSNL) to Hold

Mon, 20 Jul 2026 11:34:56 -0400

Needham analyst Mike Matson downgraded Personalis (NASDAQ: PSNL) from Buy to Hold.

The analyst comments "This morning, PSNL announced an agreement to be acquired by Tempus AI (TEM - Buy Rated, covered by Ryan MacDonald) for $16.25 per share of TEM stock or an enterprise value of ~$1.5B. At $16.25 per share, TEM is paying a 2027E EV/sales multiple of 15.5x, well above our small/mid-cap growth comp group, which trades at a median 2027E EV/sales multiple of 3.9x. We believe the premium is warranted given the strong growth in NeXT Personal, multiple Medicare reimbursement wins, and large addressable minimal residual disease

Needham Downgrades Personalis (PSNL) to Hold

Mon, 20 Jul 2026 11:34:56 -0400

Needham analyst Mike Matson downgraded Personalis (NASDAQ: PSNL) from Buy to Hold.

Needham Downgrades Personalis (PSNL) to Hold

Mon, 20 Jul 2026 11:34:56 -0400

Needham analyst Mike Matson downgraded Personalis (NASDAQ: PSNL) from Buy to Hold.

Needham Downgrades Personalis (PSNL) to Hold

Mon, 20 Jul 2026 11:34:56 -0400

Needham analyst Mike Matson downgraded Personalis (NASDAQ: PSNL) from Buy to Hold.

Form 425 Tempus AI, Inc. Filed by: Tempus AI, Inc.

Mon, 20 Jul 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260720/26787894.html

Form 425 Tempus AI, Inc. Filed by: Tempus AI, Inc.

Mon, 20 Jul 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260720/26787894.html

Form 8-K Tempus AI, Inc. For: Jul 20

Mon, 20 Jul 2026 09:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26787877.html

Form 8-K Tempus AI, Inc. For: Jul 20

Mon, 20 Jul 2026 09:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26787877.html

Tempus AI to acquire Personalis in $1.5B stock deal

Mon, 20 Jul 2026 08:30:24 -0400

Tempus AI, Inc. (NASDAQ: TEM) has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL) in a transaction valued at $1.5 billion, net of Tempus' existing ownership interest, according to a statement from the companies.

Under the terms of the deal, Personalis shareholders will receive $16.25 per share of common stock, representing a 6% premium to the most recent closing price and a 28% premium to the unaffected 30-day volume-weighted average price. The transaction is structured as a 100% stock deal, with Tempus retaining the option to pay up to 50% of consideration in cash.

Tempus and Personalis established a

Tempus AI to acquire Personalis in $1.5B stock deal

Mon, 20 Jul 2026 08:30:24 -0400

Tempus and Personalis established a